Abstract. A morbidostat is a bacteria culture device that maintains a nearly constant microbial population for the selection of drug-resistant mutants via a feedback algorithm. In this paper, the global dynamics of a microbial species undergoing sequential evolution are studied in detail to elucidate the operation of a morbidostat. The cultivation of the microbes is assumed to be under periodic dilution, and a simple threshold algorithm is used as feedback. We also prove the extinction and uniform persistence of all species with both forward and backward mutation in a sequential evolution scenario. Numerical simulations for the case of logistic growth and the Hill function for drug inhibition are also applied to verify our theoretical results. The theoretical framework elucidates the generic features of the operation of a morbidostat under drug-inhibitor-induced feedback, and will provide a useful aid for the design of experiments.
1. Introduction. Antibiotic drug resistance is a global health problem [1] . Today, clinically important bacteria are characterized by their resistance to single or multiple drugs. Antibiotic drug resistance mechanisms include (1) modification and deactivation of the antibiotic by expression of certain enzymes; (2) development of an active efflux for the drug; and (3) alteration of the intracellular drug target such as the ribosome, metabolic enzymes, or proteins involved in DNA replications or cell wall synthesis. The acquisition of high-level antibiotic resistance has been discovered in vivo. Historically, penicillin-resistant Staphylococcus aureus was discovered soon after the introduction of penicillin in clinical environments [2] . In a more recent example, antibiotic drug resistance has been studied by running the whole genome sequencing of clinical isolates from patients suffering from endocarditis (S. aureus infection of the heart muscle) and undergoing antibiotic treatment [3] . Through the course of infection over a 3-month period, a total of 35 point mutations were accumulated, many associated with the acquisition of antibiotic resistance. Increasing minimum inhibitory concentrations are also observed. Although the in vivo evolution of drug resistance can be studied retrospectively, these experiments lack systematic control over the environmental conditions for drug resistance. Alternatively, adaptive laboratory evolution (ALE) can be used to study the molecular evolution of a microbial species undergoing selection pressure from antibiotic drugs [4] . Recently, many antibiotic drug-resistant evolution experiments have attempted to elucidate the emergence of antibiotic drug resistance under well-controlled laboratory conditions. For example, Austin's group demonstrated that the drug concentration gradient can lead to the rapid emergence of antibiotic drug resistance in microfluidic devices [5] . Hwa's group later developed a compartment model [6] to explain this phenomenon, based on the earlier theoretical consideration of stochastic evolution in a source and sink scenario [7] . Advances in synthetic biology and microfluidic techniques culminated in Hwa's work on an experimentally validated model connecting the innate growth stability under the influence of translation-inhibiting antibiotic chloramphenicol to detailed biophysical processes and biochemistry such as passive diffusion and drug and enzyme interaction [8] . In short, during the
FIG. 1. A schematic of the morbidostat. A morbidostat is a continuous-culture device that automatically tunes inhibitor concentration to maintain constant growth inhibition. The assay runs in cycles of growth periods (T ) and adds dilutions with either fresh medium (blue) or drug solution (magenta) based on a threshold feedback algorithm. The population is diluted with drug solution when the total bacteria density exceeds the preset threshold value (U ).
microbial growth stage, the microbe can develop antibiotic drug resistance by constitutively expressing chloramphenicol acetyltransferase (CAT), an enzyme that deactivates chloramphenicol. The feedback model consists of an influx of chloramphenicol, microbial growth, and the CAT concentration.
Recently, a more advanced chemostat [9] known as a morbidostat has been developed with the aim of imposing drug selection pressure to induce mutations in a more systematic fashion [10] . A morbidostat is a microbial selection device that continuously adjusts the antibiotic concentration to maintain a nearly constant population. In one incarnation, as illustrated by Fig.1 , the microbial population can be monitored by recording the optical density. The addition of the drug is computer-controlled based on a prescribed feedback algorithm. Samples are frozen daily to serve as the "fossil record" of the evolution, and a small fraction is used to inoculate a fresh batch of the medium and restart another growth cycle. After the experiment has run its course, the daily frozen samples are thawed and the inhibitor concentrations are characterized. These samples are also analyzed with whole genome sequencing techniques to reveal the molecular mechanism for the drug resistance. In this work, we present a theory to not only reproduce the essential features of this mechanism, but also yield sufficient insight to provide guidelines for the analysis of the experimental data. It is our hope that the theory will aid the design of new experiments by identifying key parameters based on existing experimental data in the literature. The reminder of this paper is organized as follows. In Section 2, we specifically introduce two deterministic models for the selection of drug-resistant bacteria in the morbidostat. The first one deals with sequential forward mutation with one wild type and N mutant species. The second model deals with the same sequential evolution, but allows both forward and backward mutations. In Section 3, we study the global dynamics of the morbidostat model in two cases, and state the main results of this paper. The proofs are deferred to the Appendix in Section 6. In Section 4, we present the results of numerical simulations with plausible parameters to verify key results on the global dynamics. Section 5 is the section of conclusion and discussion.
2. Description of our models. In the simplest scenario, we can formulate the transition from a wild-type population to N mutant strains. In actual experiments conducted by Kishony's group [10] , the device maintained a nearly constant population via computercontrolled feedback. The fitness test runs in cycles of growth periods T . For the forward mutation model (see Fig. 2 ) and forward-backward mutation model (see Fig. 3 ), the growth dynamics with the nutrient substrate S under the influence of the drug inhibitor P are given by models (2.1) and (2.2), respectively.
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where i = 1, 2, ..., N − 1, and v 0 = u, u and v i are the volume densities of the wild type and mutant populations, respectively. γ is the yield constant. In Equations (2.1) and (2.2), the growth rates of the wild type and mutants are given by g 0 (S) and g i (S), which satisfy
The bacteria are assumed to consume the drug while the drug inhibits the growth of bacteria. We denote h 0 (P ) and h i (P ) as the consumption rates of inhibitor P for the wild type bacteria u and mutants v i , respectively. Furthermore, h 0 (P ) and h i (P ) are nonnegative functions which are increasing in P . The effect of the drug inhibition is described by f 0 (P ) and f i (P ) and here we use the convention that when P = 0, f 0 (0) = 1 and f i (0) = 1. Meanwhile, f ′ i (P ) < 0 since a larger drug concentration leads to stronger inhibition of the bacteria. Because the mutants have stronger resistance to the inhibitor than the wild type, we have f 0 (P ) ≤ f 1 (P ) ≤ · · · ≤ f N (P ). More generally, it is reasonable to assume that the wild type grows more slowly than the mutants in the inhibitor environment, which is our basic assumption as follows,
q i are the forward mutation rates whileq i are the backward mutation rates. We assume that the mutation rates q i andq i are quite small compared with the difference of growth rates
The resetting of the nutrient and cells at t = T n = nT (n = 0, 1, 2, · · ·) can be written as input concentration S (0) is used to refill. As a result, this dilution step contributes a term
. T − n and T + n denote the time immediately before and after the dilution step at t = nT . In mathematical terms, the definitions for T − n and T + n are given by
The resetting of the initial condition for the drug concentration P depends on the result from a feedback algorithm. Without the drug injection, the resetting of the initial condition is given by
With the drug injection and input drug concentration P (0) during the dilution step, the resetting of the initial condition is given by
To be specific, we use a threshold algorithm as an example. The drug injection is invoked if the following condition is fulfilled,
where U is the threshold population density.
3. Statement of main results. We first do some simplifications for models (2.1) and (2.2) more mathematically tractable.
, we obtain the following scaled models of models (2.1) and (2.2), respectively,
for T n−1 < t < T n , and the resetting conditions at t = T n are 
In other words, all the mutants go extinction, and inhibitor P goes to 0 in the long-term in this case.
In this case, the most resistant microbe v N will survive while inhibitor P goes to 0 in the long-term. (ii) There exist 0 <d 1 <d 2 < 1, 4. Numerical simulation. In this section, we summarize the conditions where simulations are done with realistic parameters.
For simplicity, we assume that both the wild type and the mutants have equal uptake function and the growth takes the logistic form, namely,
The consumption functions h 0 (P ) and h i (P ) are assumed to take the Holling Type II function form [15] ,
We assume the functions f 0 (P ) and f i (P ) take the Hill function form of order L, which are
where i = 1, 2, 3, · · · , N . Note that the order L stems from the allosteric cooperativity of the drug inhibition [18] . The drug inhibition effects depend on the detailed mechanism. For example, they can result from the binding of the antibiotic drug to the metabolic enzyme that synthesizes the key precursor of biomass production of the bacteria. Taking trimethoprim (TMP) as a specific example, this antibiotic binds to dihydrofolate reductase (DHFR), an enzyme that controls the biosynthesis of folic acid. The mutation of the gene encoding DHFR will modify the binding affinity of TMP [10] . The parameters K 0 and K i in (4.2) can actually be extracted from the experimental values of IC 50 , defined as the drug inhibitor concentration at which the growth rate is 50% of the maximal growth rate. The sample volume in the culture vessel of the morbidostat is 10 ml, and the confluent density of EColi is typically 10 9 cell/ml. For simplicity, we assume that the morbidostat operates at around 10% of the confluent density, which is set by the threshold population U in (2.5). We can conveniently set the yield constant γ to be 1, so that one unit of substrate density will transform to one unit of bacteria. With the volume units set to 0.1 nl, the input substrate S (0) = 100 corresponds to 10 9 cell/ml. The constants K 0 and K i in the drug inhibition function are set to 1 and 10 i , and the order in the Hill function L = 1, 2, 3. We first consider the forward mutation rates q = 10 −4 hr −1 . Typically, the dilution ratio d = 0.9 and growth period T = 0.2 hr are set such that the effective dilution rate ln(1 − d)/T = 0.5hr −1 . The growth rate is set by the constant m to be 8 × 10 −3 hr −1 in the logistic growth function. The initial conditions are S(0) = 100, u(0) = 0.01, v(0) = 0, and P (0) = 0. We demonstrate our theoretical results by conducting the following simulations.
4.1. Single mutant with forward mutations. We first assume that there is wild type u and single mutant v in the morbidostat and there is no backward mutation. Then we have the morbidostat model in the following form, From the simulation results, we can see the inhibitor concentration P oscillates between 0 andP , which is P ∈ (0, 2.8563) while the bacteria density v will be maintained at nearly constant, and furthermore v ∈ (v,ṽ) = (10.1630, 28.9819). Next, we demonstrate the long-time dynamics of morbidostat model using different U in three cases, respectively. We choose P (0) = 10 and d = 0.9 in the following simulations. When U = 33, it impliesz <w < dU , which is subcase (a) in Theorem 3.1. The long-term dynamics of model (4.3) with resetting conditions (4.4) are shown in Fig.6 . The insets show the oscillations of the mutant and substrate concentrations in the last 100 dilution steps. As the figure shows, v n →w and P n → 0 as n → ∞ in this case. In other words, the fixed point (ṽ, 0) = (w, 0) attracts all positive initial data, which verifies Theorem 3.1.
The dynamics of model (4.3) with resetting conditions (4.4) with U = 10 is shown in Fig.7 . In this case we have dU <z <w, and the two conditions in the subcase (b) in Theorem 3.1 can be verified using the parameters given above. The figure shows that v n →v and P n →P as n → ∞ in this case. More precisely, there exists a positive fixed point (v,P ) for the morbidostat model (4.3) with resetting conditions (4.4), which agrees well with the result in subcase (b) in Theorem 3.1. concentration P oscillates between 0 andP , while the bacteria density v will be maintained nearly constant.
To make the situations in subcase (c) in Theorem 3.1 more clearly, we choose P (0) = 10, U = 15, and simulate the morbidostat model (4.3) with resetting conditions (4.4) with some more parameters.
We first fix the mutation rate at q = 10 −6 , and let L vary from 1 to 3. Both the long-term concentrations of nutrient, inhibitor and the cell densities are shown in Fig.9 . It indicates that the mutant v drives u to extinction in each cases, and the mutant density is maintained nearly constant. The inhibitor concentration P oscillated between 0 and P (0) . As L grows bigger, more inhibitor P is needed to inhibit the bacteria and to maintain v at a nearly constant level. However, the time needed for v to take over is almost same although the hill functional order L differ.
Next, we fix the hill functional order at L = 3, and make the mutation rate q vary from 10 −4 to 10 −8 . Both the concentrations of nutrient, inhibitor and the cell densities are shown in Fig.10 . The mutant v still drives u to extinction in each case, and the mutant density is maintained nearly constant. It takes longer time for mutant v to take over when the mutation rate is lower. The inhibitor concentration P oscillated between 0 and P (0) . And the inhibitor concentration P is almost same although mutation rates are different.
From Fig.6 to Fig.10 , we have the mutant v will drive wild type bacteria u to extinction in the long-term no matter what the threshold U is, and no matter how small the mutation rate q and the Hill functional order L is. It shows that the exclusion principle holds, which agrees well with our theoretical analysis in Theorem 3.1.
4.2. Two mutants with both forward and backward mutations. We then assume there is wild type u and two mutants v 1 and v 2 in the morbidostat, and assume that the mutants are with forward-backward mutations. Then we have the morbidostat model in the following form, 
The simulation results of system (4.5) with resetting conditions (4.6) show that either all the cells go to extinction (see Fig.11 ) or persist (see Fig.12 and Fig.13 ) in the morbidostat, which verifies our theoretical results in Theorem 3.2. In Fig.12 , the most resistant mutant dominates the final population with the coexistence of a small fraction of other species (wild type and mutant 1) due to the assumption of small mutation rates as compared to the growth rates g i (S (0) ) (i = 0, 1, 2). In Fig.13 , the coexistence of all the species is obvious when q 0 = q 1 =q 0 =q 1 = 0.05. 5. Conclusion and discussion. In conclusion, we have outlined a mechanistic theory to describe the outcome of microbial growth in a morbidostat. The theory incorporates a simple threshold algorithm to recapitulate the feedback effects due to antibiotic drug inhibition. In the simplest scenario, we considered the case of sequential evolution with only forward mutation. This model serves as a concrete example for different modes of operation of the morbidostat. The global dynamics were discussed for three cases. The main result of Theorem 3.1 for Case (i) describes a total washout if 0 < d < exp (−g N (S (0) )T ), as expected from a serial dilution transfer cultivation [12] . And there are three possible outcomes when the most resistant mutant survival, which are stated in Case (ii). Subcase (a) describes the dilution of the drug and survival of the most resistant mutant. Subcase (b) describes a system that is trying to pump as hard as possible to suppress the total population. As a result, the final inhibitor concentration asymptotically approached the input inhibitor concentration P (0) . Subcase (c) describes the case of oscillation due to the simple threshold feedback used in our analysis. All three subcases were verified using numerical simulations. When backward mutation was included in the evolution of the mutants, the long-term outcome in the morbidostat illustrated the uniform persistence case. We included a simple three-species case to demonstrate these two scenarios.
Although our model considered sequential evolution with mutation, it can be generalized to consider the microbial ecology of a serial transfer dilution bio-reactor with feedback and constant exchange rates between the species. In real experiments, the scenario is much more complicated than the models considered here. In general, it is possible that multiple mutants would be accessible to the wild-type species, and a more complicated evolution could be incorporated into the simulations [19] . Experiments could also be conducted to evolve the bacteria so as to acquire not only single drug resistance, but also multiple drug resistance. The theory outlined here can be generalized to include these scenarios in a straightforward way in the computer simulations. With the theory presented here, one could in principle calculate the population dynamics step by step for a new experiment, or reconcile the experimental results after an experiment has been completed. Finally, our model is deterministic in nature, whereas microbial mutation is stochastic. It will be interesting to generalize our model or simulation to take account of the stochastic nature of the mutation [8] . 6. Appendix. For the scaled models (3.1) and (3.2) with resetting conditions (3.3), we have the following results.
FIG. 10. Cell, substrate, and inhibitor densities of system (4.3) with resetting conditions (4.4) when q = 10 −4 (upper panel), 10 −6 (middle panel), and 10 −8 (lower panel), respectively. Wild type u goes extinction in each case, while mutant v persists at a nearly constant level. It takes longer time for the mutant to take over as the mutation rate becomes lower. In this figure, we use S

FIG. 11. Extinction of all the microbes of system (4.5) with resetting conditions (4.6). In this case, all the cells and inhibitor go to extinction in the morbidostat, while the substrate persists at a fixed level. In this figure, we use
LEMMA 6.1. The total population density of the nutrient and bacteria in the morbidostat converges to S (0) . In other words, we have S(T
+ n ) + u(T + n ) + ∑ N i=1 v i (T + n ) → S (0) as n → ∞. LEMMA 6.2
. For the system (3.1) and (3.2) with resetting conditions (3.3), there exists some δ > 0 such that S(t) ≥ δ > 0 for all t ≥ 0.
Lemma 6.1 states a conservation of species, while Lemma 6.2 is a technical lemma.
Proof of Lemma 6.1. Proof. Adding the first N + 2 equations of models (3.1) and (3.2) together respectively, and define then the following single equation is obtained,
C(t) = S(t) + u(t) +
It follows at once that,
Together with the resetting condition at t = T , leads to
FIG. 14. Operation diagrams when there are only forward mutations: Region A is the extinction region that all the species go to extinction; Region B is the region only the most resistant microbe survives; Region C is the region that the most resistant microbe survives and inhibitor oscillates; Region D is the region that the most resistant microbe survives and inhibitor persists at a fixed value.
Similarly, the total population density of nutrient S, bacteria u and v i right after the second period takes the following form,
be the total population following the nth dilution cycle. Then,
as n → ∞, and
for all t ∈ [T n , T n+1 ] as n → ∞. That completes our proof.
Proof of Lemma 6.2. Proof. For the morbisostat models (3.1) and (3.2) with condition (3.3), we have
FIG. 15. Operation diagrams when there are both forward and backward mutations: Region A is the extinction region that all the species go to extinction; Region B is the region only the most resistant microbe survives; Region C is the region that the most resistant microbe survives and inhibitor oscillates; Region D is the region that the most resistant microbe survives and inhibitor persists at a fixed value.
≥ −g
Let S * (t) be the solution of the following system,
* (t)} and δ < min 0≤t≤T J 0 {S(t)}, we then have S(t) > δ for all t ≥ 0. That completes our proof.
Define a map Q by
where v = (v 1 , v 2 , ..., v N 
are the solutions of (3.1) or (3.2) with initial conditions
be the values of the vector of the population densities immediately following the nth dilution cycle, then 
Proof of Lemma 6.3. Proof. From model (3.1), if letting ω(t) = u(t)
Integrating both sides of (6.7) over the interval (0, T ),
Which implies,
Similarly, for the last mutants v N , we have the following equation,
Multiply (6.8) by (6.9) , it is easy to check,
We apply the same technique during the second periodic cycle (T, 2T ), then the following inequality is obtained,
Similarly, during the ith periodic cycle ((i − 1)T, iT ), we have
Multiply both sides of all the inequalities above, we have
From Lemmas 6.1 and 6.3, the forward mutation morbidostat model (3.1) with resetting conditions (3.3) can be reduced to the following limiting system.
We denote (v N (t), P (t)) as the solution of model (6.10) with resetting conditions (6.11), and
The long-term dynamics of the morbidostat model is our concern. In order to analyze the dynamics of the morbidostat, we will firstly study two comparison systems.
Since
, the first comparison system to be studied is as follows,
Let w(t) be the solution of the problem (6.12) and denote w n as the population density right after the n-th dilution cycle, then we know w n = w(T + n ). Let x 0 = w 0 , and define map w(t, w 0 ) ) as the solution of the following equation,
with initial condition w(0) = w 0 .
We will next study the existence and stability of the fixed point of system (6.12). Based on the results in [14] , we have the following results.
LEMMA 6.4. For system (6.12) ,
, then the extinction fixed pointw = 0 is globally attracting.
there is a unique positive fixed pointw > 0 satisfying Q 1 (w) =w and it attracts all positive initial data, in other words,
). The second comparison system is as follows ,
We denote z(t) as the solution of problem (6.14), and z n = z(T + n ) as the population density right after the n-th dilution cycle. Define map Q 2 by Q 2 (z 0 ) = z 1 = dz(T, z 0 ). For system (6.14), we have a similar result as the first comparison system. The post-dilution density sequence z n converges to a fixed point: z n →z; where Q 2 (z) =z. This fixed point may or may not be the trivial fixed pointz = 0. And the stability of the fixed point can be given by the following Lemma. LEMMA 6.5. For system (6.14) , we have the following two results,
, then the extinction fixed pointz = 0 is globally attracting;
there is a unique positive fixed pointz > 0 satisfying Q 2 (z) =z and it attracts all positive initial data, in other words,
) . Furthermore, at the fixed point
from(6.10), (6.12) and (6.14), it follows that
Therefore, we havez ≤ (v N ) n ≤w for n is sufficiently large. For the fixed points of system (6.12) and (6.14)w =w(d),z =z(d), we have the following results. LEMMA 6.6. Let U < S (0) ,
Proof of Lemma 6.4. Proof. Clearly, Q 1 (0) = 0 and Q 1 is strictly increasing by uniqueness of solutions of the initial value problem (6.13). Because w = S (0) is an equilibrium of (6.13), we have
for all n ≥ 1. Therefore, the post-dilution density sequence converges to a fixed point: w n → w; where Q 1 (w) =w. This fixed point may or may not be the trivial fixed pointw = 0. The stability of the fixed point is determined by
Then the stability of the trivial fixed point is determined by
where x(t) = ∂w ∂w0 (t) satisfies the variational equation Differentiating both sides of (6.15) with respect to d, yields (6.17) for t ∈ (0, T ), differentiating both sides of (6.17) with respect to w 0 , we have 
Therefore,
Then, we have
Therefore, from (6.18) and (6.19) we have
By applying the same procedure to the second comparison system (6.14), we havez
is also an increasing function of d. The proof of (iii) follows directly from (i) and (ii) and the assumption U < S (0) . That completes our proof.
We will now study the dynamics of the solution of the limiting system (6.10) with resetting conditions (6.11) . According to the relations of fixed pointsz,w and threshold U , we have the main results in the following three cases.
Case 1: no drug inhibitor case of the limiting system. If d < d 1 , we havez <w ≤ dU , and hence (v N ) n ≤ dU for all large n, then the inhibitor P dilutes in every dilution cycle. Therefore, there is no inhibitor pumped into the morbidostat. And the inhibitor concentration P n takes the following form after the nth dilution cycle,
, it is obvious that P n → 0 as n → ∞. System (6.10) with resetting condition (6.11) can be reduced to the limiting system (6.12). Thus, in this case, we have (v N ) n →w as n → ∞. More precisely, we have the following results. LEMMA 6.7. For the limiting system (6.10) with resetting conditions (6.11) 
, then the extinction fixed point (0, 0) is globally attracting. Case 2: hard inhibitor pumping of the limiting system. If d > d 2 , we have dU < z ≤w, and hence (v N ) n > dU for all large n. In this case, the inhibitor P will be pumped into the morbidostat in every dilution cycle. In other words, the resetting of inhibitor P will always follow the rule P n = dP (nT ) + (1 − d)P (0) for n = 1, 2, 3, · · · . Thus, after the nth dilution cycle, the inhibitor concentration P n satisfies
In this case, system (6.10) with resetting condition (6.11) can be reduced to the following limiting system, Without loss of generality, we denote this fixed point as (v N ,P ). Since (v N ) n > dU for n large, we havev N > 0 and P > 0. Therefore, there exist a positive fixed point (v N ,P ) for system (6.20) , and it satisfies the following conditions. REMARK 6.2. If h N (P ) = 0, i.e. the last mutant does not consume inhibitor, then it is easy to verify thatP = P (0) and P n → P (0) as n → ∞. Then we consider the limiting system (6.14) from Lemma 6.5, the dynamical behavior of
, P (t,P )) be the solutions of system (6.20) with initial value (v N ,P ), then
Case 3: oscillation of the limiting system. If d 1 < d < d 2 , we havez < dU <w in this case. Thus the resetting of P will follow the dilution rule P n = dP n−1 if (v N ) n−1 < dU , otherwise it will follow the resetting rule P n = dP n−1 + (1 − d)P (0) . Therefore, the inhibitor concentration may oscillate in this case as the system is trying to maintain constant bacteria density v N through feedback. We will also demonstrate it by numerical simulation in Section 4.
Proof of Theorem 3.1. Based on the above analysis, we complete the proof of Theorem 3.1.
Global dynamics of the Morbidostat model with both forward and backward mutations. When there are both forward and backward mutations in the morbidostat, we have the following lemmas and main results in two cases.
LEMMA 6.8. 
, then for the cells in the morbidostat, we have
To study the limiting system (6.21), by hypothesis (2.3) we introduce two comparison systems of it. The first comparison system is (6.12), which is the same one as in Section 6. The second comparison system takes the form of
We denote κ(t) as the solution of problem (6.22) , and κ n = κ(T + n ) as the population density right after the n-th dilution cycle. Define map Q 3 by Q 3 (κ 0 ) = κ 1 = dκ(T, κ 0 ). For system (6.22), we have a similar result as the comparison systems (6.12) and (6.14). The post-dilution density sequence κ n converges to a fixed point: κ n →κ; where Q 3 (κ) =κ. This fixed point may or may not be the trivial fixed pointκ = 0. And the stability of the fixed point can be given by the following Lemma. LEMMA 6.10. For system (6.22) , we have the following two results,
, then the extinction fixed pointκ = 0 is globally attracting; 
) . Furthermore, at the fixed point we have
Therefore, we haveκ ≤ µ n ≤w for n is sufficiently large.
For the fixed points of system (6.12) and (6.22)w =w(d),κ =κ(d), we have the following results.
The proof of Lemma 6.11 is similar with the proof of Lemma 6.6, therefore we omit the details of the proof here. Proof of Lemma 6.8. Proof. We may assume 0 < j < N, the proofs for the cases with j = 0 or j = N are the same as that for 0 < j < N.
It is easy to verify that from the equations of (3.2) and Lemma 6.1, we have
and
, and f ′ j (P ) < 0, we have | 
(X). It is obvious that F (X) ≤ G(X).
Note that (6.26) is a cooperative system, by Kamke's Theorem, we have (S n , u n , (v) n , P n ) ≤ (Ŝ n ,û n , (v) n ,P n ), (6.27) where (Ŝ n ,û n , (v) n ,P n ) =Q We will next prove that the last mutant v N dominates the other populations if the backward mutation rates are sufficiently small. Let (S n ,ũ n , (ṽ) n ,P n ) be the solution of system (3.1) with resetting conditions (3.3). From Lemma 6.3,ũ n + ∑ N −1 i=1 (ṽ i ) n → 0 as n → ∞. Hence given ϵ > 0, there exists n 0 > 0 such that 0 <ũ n + ∑ N −1 i=1 (ṽ i ) n < ϵ for all n ≥ n 0 . Consider the fixed interval [n 0 T, 2n 0 T ] and the solution (S n , u n , (v) n , P n ) of the system (3.2) with resetting conditions (3.3). From continuous dependence properties on parameters [17] , it follows that if the backward mutation ratesq 0 ,q 1 ,· · ·,q N −1 are sufficiently close to 0, then |(S n , u n , (v) n , P n ) − (S n ,ũ n , (ṽ) n ,P n )| < ϵ for all n ∈ [n 0 , 2n 0 ]. It implies that Proof of Theorem 3.2. By Theorem 6.9, Lemma 6.10, Lemma 6.11 and Remark 6.3, we complete the proof of Theorem 3.2.
